COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

HOPE-Epilepsy Trial (HOPE-Epilepsy)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01744275
Recruitment Status : Suspended (Lack of funding)
First Posted : December 6, 2012
Last Update Posted : February 27, 2014
Information provided by (Responsible Party):
Hospital do Coracao

Brief Summary:
This a multi-center study to examine whether supplementation with omega 3 fatty acids will reduce seizure frequency in patients with epilepsy .

Condition or disease Intervention/treatment Phase
Epilepsy Dietary Supplement: Omega 3 fatty acids Dietary Supplement: corn oil Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 370 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: High Dose Omega 3 Fatty Acids Supplementation in Patients With Epilepsy : The HOPE-Epilepsy Trial
Study Start Date : July 2013
Estimated Primary Completion Date : July 2014
Estimated Study Completion Date : July 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy Seizures

Arm Intervention/treatment
Placebo Comparator: Placebo
Dietary Supplement: corn oil

Experimental: Omega 3 fatty acids supplementation
Omega 3 fatty acids capsules
Dietary Supplement: Omega 3 fatty acids

Primary Outcome Measures :
  1. Seizure Frequency [ Time Frame: 18 months ]
    number of seizures during the treatment period

Secondary Outcome Measures :
  1. categorized seizure frequency [ Time Frame: 18 months ]
    number of crises categorized as: generalized, focal with disconnection and focal without disconnection

  2. Percentage of overall seizure frequency modification [ Time Frame: 18 months ]
    percentage of reduction or increase in seizure frequency from baseline til the end of treatment period

  3. Time Free of seizures during treatment [ Time Frame: 12 months ]
  4. Reduction in seizure frequency [ Time Frame: 12 months ]
  5. Quality of Life [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients with active Epilepsy

Exclusion Criteria:

  • pregnant women or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01744275

Layout table for location information
Research Institute, Hospital do Coração
São Paulo, Brazil, 04005-909
Sponsors and Collaborators
Hospital do Coracao
Layout table for investigator information
Principal Investigator: M J Carrion, MD Hospital do Coracao
Study Chair: O Berwanger, PhD Hospital do Coracao
Study Chair: R D Lopes, PhD BCRI
Study Chair: F A Scorza, PhD Federal University of São Paulo
Layout table for additonal information
Responsible Party: Hospital do Coracao Identifier: NCT01744275    
Other Study ID Numbers: HCor
Research Institute - HCor ( Other Identifier: HCor )
First Posted: December 6, 2012    Key Record Dates
Last Update Posted: February 27, 2014
Last Verified: February 2014
Keywords provided by Hospital do Coracao:
Omega 3 fatty acids
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases